Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04938726 · ClinicalTrials.gov registry record · NA

Ketone Supplementation in Cystic Fibrosis

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
15
Enrollment target

NCT04938726: Completed NA study, sponsored by University of Alabama at Birmingham.

NCT04938726 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04938726, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

This study will examine the effects of a novel ketone monester supplement on patients with cystic fibrosis experiencing an acute pulmonary exacerbation requiring hospitalization. Patients will undergo standard testing along with blood sampling to examine concentrations of inflammatory markers. Patients will then receive the ketone supplement for 5 days followed by post-testing to examine changes in pulmonary function and inflammatory markers

Primary Outcome

FEV1.0 (L/sec)

Interventions

  • DIETARY_SUPPLEMENT Ketone Monoester

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2021-11-01
Est. Completion 2023-04-30
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the finished NCT04938726 record still lists

NCT04938726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Ketone Monoester is the first listed.

NCT04938726 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04938726 about?

NCT04938726 is a clinical study titled "Ketone Supplementation in Cystic Fibrosis". This study will examine the effects of a novel ketone monester supplement on patients with cystic fibrosis experiencing an acute pulmonary exacerbation requiring hospitalization. Patients will undergo standard testing along with blood sampling to examine concentrations of inflammatory markers. Patie...

What is the current status of trial NCT04938726?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2021-11-01. Estimated completion is 2023-04-30.

What interventions are being tested in trial NCT04938726?

The interventions under investigation include: Ketone Monoester (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04938726?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04938726's enrollment target sits among peer trials

15 1881st of 2000 higher than 92 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04938726, the US trial registry maintained by the National Library of Medicine. NCT04938726 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.